Every Form 4 that Microbot Med Inc (MBOT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MBOT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MBOT filings page.
Microbot Medical Inc. director Aileen Ptucha Stockburger received a grant of stock options covering 10,000 shares of common stock. The options have an exercise price of $2.37 per share, were granted on April 1, 2026, and are scheduled to expire on April 1, 2036.
Microbot Medical Inc. director Madden Martin J. received a grant of stock options representing 10,000 shares of common stock. The options have an exercise price of $2.37 per share, were granted on April 1, 2026, and expire on April 1, 2036.
This is a compensation-related award, not an open-market purchase or sale, and leaves the director holding 10,000 options following the transaction.
Microbot Medical Inc. director Wenderow Tal Baruch received a grant of stock options, giving the right to buy 10,000 shares of common stock. The options have an exercise price of $2.37 per share and expire on April 1, 2036. Following this grant, Baruch holds stock options covering 10,000 shares directly.
Microbot Medical Inc. director David James Wilson received a grant of stock options covering 10,000 shares of common stock. The options were awarded at an exercise price of $2.37 per share, carry no upfront cost, and were granted on April 1, 2026.
These options give him the right to buy 10,000 shares of Microbot Medical common stock at $2.37 per share until their expiration on April 1, 2036. After this grant, he holds 10,000 stock options directly, with no additional derivative positions shown in this filing.
Microbot Medical Inc. director Burell Scott R reported receiving a grant of stock options. On April 1, 2026, he was awarded options to acquire 10,000 shares of common stock at an exercise price of $2.37 per share, expiring on April 1, 2036. Following this grant, he holds stock options covering 10,000 underlying shares directly.
Microbot Medical Inc. director Laxminarain Prattipati received a grant of stock options covering 10,000 shares of common stock. The options have an exercise price of $2.37 per share, were granted on April 1, 2026, and expire on April 1, 2036.
Following this grant, Prattipati holds stock options for 10,000 shares directly. This is a compensation-related award, not an open‑market purchase or sale of Microbot Medical common stock.
Gadot Harel reported acquisition or exercise transactions in this Form 4 filing.
Microbot Medical Inc. reported that Chairman, President and CEO Harel Gadot received a grant of stock options covering 480,000 shares of common stock. These options were awarded under the company’s 2020 Omnibus Performance Award Plan.
According to the grant terms, 25% of the option vests and becomes exercisable on August 18, 2026. The remaining 75% vests and becomes exercisable in equal installments on a quarterly basis over the following 30 months, subject to the plan’s provisions on possible acceleration or forfeiture.
Diaz-Cartelle Juan reported acquisition or exercise transactions in this Form 4 filing.
Microbot Medical Inc. reported that Chief Medical Officer Juan Diaz-Cartelle received a grant of stock options covering 105,000 shares of common stock. These options were awarded at no cost as part of his compensation.
Under the company’s 2020 Omnibus Performance Award Plan, 25% of the options will vest and become exercisable on August 18, 2026. The remaining 75% will vest in equal installments on a quarterly basis over the following 30 months, subject to possible acceleration or forfeiture under the plan terms.
Sharon Simon reported acquisition or exercise transactions in this Form 4 filing.
Microbot Medical Inc. reported that General Manager and CTO Sharon Simon was granted stock options covering 105,000 shares of common stock. According to the company’s 2020 Omnibus Performance Award Plan, 25% of the options vest and become exercisable on August 18, 2026, with the remaining 75% vesting in equal quarterly installments over the following 30 months, subject to the plan’s acceleration or forfeiture provisions.
Vaknin Rachel reported acquisition or exercise transactions in this Form 4 filing.
Microbot Medical Inc. reported that its Chief Financial Officer, Rachel Vaknin, received a grant of stock options covering 105,000 shares of common stock. The award is a right to buy shares under the company’s 2020 Omnibus Performance Award Plan, as amended.
According to the grant terms, 25% of the options will vest and become exercisable on August 18, 2026. The remaining 75% will vest and become exercisable in equal installments on a quarterly basis over the following 30 months, subject to possible acceleration or forfeiture under the plan.